Pravastatin coronary artery disease

In 1998 the REGRESS group published data, which showed that the TaqlB polymorphism in intron 1 of the cholesterol-ester transfer protein (CETP) gene predicts whether men with coronary artery disease would benefit from treatment with pravastatin or not [60]. Pravastatin therapy slowed the progression of coronary athero-... 

Lipoprotein (a) is an independent risk factor for coronary artery disease [68]. It consists of two components an LDL particle and apolipoprotein (a) which are linked by a disulfide bridge. Apo(a) reveals a genetically determined size polymorphism, resulting from a variable number of plasminogen kringle IV-type repeats [69]. Statins either do not affect Lp(a) or may even increase Lp(a) [70, 71]. In a study of 51 FH patients, treated with 40 mgd 1 pravastatin, it has been shown that the increase in Lp(a) was greatest in patients with the low molecular-weight apo(a) phenotypes [70]. 

The Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary artery disease and a broad base of initial cholesterol levels. N Engl J Med 1998 339 1349-1357. 

Tamura A, Mikuriya Y, Nasu M. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group. Am J Cardiol 1997 79 893-896. 

Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. GuideUnes for lowering lipids to reduce coronary artery disease risk a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am. J. Cardiol 2003 91 (5A Suppl S) 11C-17C. 

Atherosclerotic cardiovascular disease HMG co-A reductase inhibitors Lovastatin Pravastatin Simvastatin Primary and secondary prevention of coronary heart disease (CHD) reduced hospitalizations, percutaneous transluminal coronary angioplasties (PTCA), and coronary artery bypass graft surgeries (CABG) reduced all-cause mortality 4S AFCAPS CARE LIPID WOSCOPS >30,000 7,8... 

---